CRIS CURIS INC

$0.44 +18.45%

Healthcare · Biological Products, (No Diagnostic Substances)

CURIS INC (CRIS) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $17 million. Shares last traded at $0.44, 83.1% below their 52-week high. Over the past year the stock is down 82.3%. Net profit margin is -80.3%, below the peer median of 6.3%. Revenue declined 13.4% year over year.

Market Cap

$17M

Shares Out

39.0M

EPS (TTM)

$-6.51

P/E Ratio

—

P/S Ratio

1.80

P/B Ratio

1.34

Dividend / Share

—

Dividend Yield

—

52-Week High

$2.57

52-Week Low

$0.37

Volume

8,991

Avg Vol (3m)

10,565.746

Performance

+1.30%

-8.53%

-42.78%

-62.47%

YTD

-55.79%

-82.30%

Chart

Full chart →

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)

41.59

SMA (50)

$0.53

SMA (200)

$1.04

Price vs SMA50

-17.98%

Price vs SMA200

-58.14%

ATR (14)

$0.04

Financials

Revenue

$9M

Net Income

$-8M

Gross Margin

—

Operating Margin

-60.5%

Net Margin

-80.3%

Return on Equity

-59.7%

Return on Assets

-25.5%

Current Ratio

1.11

Debt / Equity

0.00

Revenue Growth (YoY)

-13.4%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

Period	EPS (diluted)	Reported
Q1 2026	$-1.25	2026-05-13
FY 2025	$-0.58	2026-03-24
Q3 2025	$-2.19	2025-11-06
Q2 2025	$-1.82	2025-08-05
Q1 2026	$-1.25	2026-05-13
FY 2025	$-6.88	2026-03-24

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

CRIS vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers

1.80 / 5.21 med

-66% discount

Net margin vs peers

-80.3% / 6.3% med

below median

1–14 of 14


AMGN	Amgen	$182.1B	23.62	4.96	21.0%	-1.27%
GILD	Gilead Sciences	$153.5B	18.04	5.21	28.9%	-1.46%
RVMD	Revolution Medicines, Inc.	$34.6B	-30.62	—	—	+3.14%
BIIB	Biogen	$29.0B	22.44	2.93	13.1%	-1.15%
MRNA	Moderna	$25.4B	-8.99	—	—	+3.22%
NBIX	Neurocrine Biosciences Inc	$15.9B	33.24	5.56	16.7%	-0.48%
EXEL	Exelixis, Inc.	$13.1B	16.68	5.62	33.7%	-1.04%
KRYS	Krystal Biotech, Inc.	$10.2B	50.02	26.33	52.6%	+1.68%
TECH	Bio-Techne	$9.1B	123.61	7.44	6.0%	+5.36%
HALO	Halozyme Therapeutics, Inc.	$8.1B	25.67	5.82	22.7%	-0.03%
IBRX	Immunitybio, Inc.	$7.7B	-21.87	—	—	+5.01%
RGEN	Repligen Corp	$7.4B	152.27	10.08	6.6%	-1.20%
KYMR	Kymera Therapeutics, Inc.	$7.4B	23.88	—	—	+0.44%
PCVX	Vaxcyte, Inc.	$7.4B	-9688.00	—	—	+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.